Cencora Inc. (COR)
Healthcare
Medical Distribution
311.30 $
-0.3%
vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Cencora Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
58.4$B
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
195Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
94.6%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
0.6
Performance
Perf. 1M
Price performance over the last month.
5.20%
Perf. 3M
Price performance over the last 3 months.
-9.60%
Perf. 6M
Price performance over the last 6 months.
-16.80%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
-16.40%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-24.0%
Perf. 1Y
Price performance over the last 12 months.
-2.22%
Perf. 3Y
Price performance over the last 3 years.
53.70%
Perf. 5Y
Price performance over the last 5 years.
159.36%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
23.8
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
14.8
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
0.6
P/B
Price-to-book ratio: market value relative to book equity.
17.8
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
0.2
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
13.5
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
37.5
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
3.8%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
1.7%
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
0.8%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
107.1%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
3.5%
Balance Sheet & Safety
very low
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
4.2%
negative equity
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
-0.9
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
3.72
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
5 out of 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
3.80%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
128.30%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
9.31%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
6.39%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
11.40%
Dividend
Dividend Yield
Annual dividend divided by the current price: what percentage of your investment comes back as a payout each year.
0.81%
Dividend Per Share (TTM)
Sum of dividends paid per share over the last 12 months.
2.35$
Payout Ratio
Share of profit paid out as dividends. Over 100% means the company is paying out more than it earns — not sustainable long-term.
14.1%
Years Without a Cut
How many years in a row the dividend hasn't been cut — a measure of reliability.
5Years
Increase Streak
How many years in a row the dividend has been raised — the gold standard for dividend payers.
5Years
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
4
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
24
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
88
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
5 out of 9
Fundamental Rating
Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below.
C (49 out of 100)
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
3.72
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
Current Price
311.30 $
Price Target (average)
351.00 $
The price target sits 12.8% above the current price.
- Consensus
- Strong Buy
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
5. Aug 2026
· before the open
· Q2 2026
- Expected Earnings per Share
- 4.37 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 2.50 | -16.00 | 81,487 | 12.80 | 0.60 | -2,719 | -2,825 |
| 2025: Q1 | 3.68 | 75.90 | 75,454 | 10.30 | 1.00 | 3,351 | 3,222 |
| 2025: Q2 | 3.52 | 45.70 | 80,664 | 8.70 | 0.90 | 109 | -74 |
| 2025: Q3 | -1.75 | -10,475.20 | 83,729 | 5.90 | -0.40 | 3,133 | 2,884 |
| 2025: Q4 | 2.87 | 14.50 | 85,932 | 5.50 | 0.70 | -2,305 | -2,425 |
| 2026: Q1 | 8.40 | 128.30 | 78,356 | 3.80 | 2.10 | 1,339 | 1,173 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Cencora, Inc. beschafft und vertreibt pharmazeutische Produkte in den USA und international.
| Employees | 47,000 |
|---|---|
| Headquarters | Conshohocken, PA |
| Website | cencora.com |
| IPO Date | 4. Apr 1995 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert P. Mauch Ph.D., PharmD | President, CEO & Director | 1967 |
| James F. Cleary Jr. | Executive VP & CFO | 1963 |
| Elizabeth S. Campbell J.D. | Executive VP & Chief Legal Officer | 1975 |
| Silvana Battaglia | Executive VP & Chief Human Resources Officer | 1968 |
| Lazarus Krikorian | Senior VP, Chief Accounting Officer & Corporate Controller | 1965 |
| Pawan Singh Verma | Executive VP and Chief Data & Information Officer | 1977 |
| Bennett S. Murphy | Senior VP Of Investor Relations & Enterprise Productivity and Treasury | – |
| Richard Tremonte | EVP and President of U.S. Pharmaceuticals & Animal Health | – |
| Juan Guerra | EVP & President of International Business Group | – |
| François Mandeville | Executive VP and Chief Strategy and M&A Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.